Immunome Net Worth
Immunome Net Worth Breakdown | IMNM |
Immunome Net Worth Analysis
Immunome's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Immunome's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Immunome's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Immunome's net worth analysis. One common approach is to calculate Immunome's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Immunome's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Immunome's net worth. This approach calculates the present value of Immunome's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Immunome's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Immunome's net worth. This involves comparing Immunome's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Immunome's net worth relative to its peers.
Enterprise Value |
|
To determine if Immunome is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunome's net worth research are outlined below:
| Immunome generated a negative expected return over the last 90 days | |
| Immunome has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 14.02 M. Net Loss for the year was (106.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunome currently holds about 34.65 M in cash with (7.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86. | |
| Immunome has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: Immunome files to sell 1.80M shares of common stocks by selling shareholders |
Immunome uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunome. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunome's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Immunome's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunome is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunome backward and forwards among themselves. Immunome's institutional investor refers to the entity that pools money to purchase Immunome's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 1.1 M | Vestal Point Capital Lp | 2024-06-30 | 1000 K | Woodline Partners Lp | 2024-06-30 | 922.9 K | Avidity Partners Management Lp | 2024-06-30 | 873.9 K | Brown Advisory Holdings Inc | 2024-09-30 | 860.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 743.9 K | Victory Capital Management Inc. | 2024-09-30 | 730.8 K | Tang Capital Management Llc | 2024-06-30 | 720 K | Sofinnova Ventures | 2024-06-30 | 655.7 K | T. Rowe Price Investment Management,inc. | 2024-09-30 | 5.8 M | Redmile Group, Llc | 2024-09-30 | 4.9 M |
Follow Immunome's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 612.93 M.Market Cap |
|
Project Immunome's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.72) | (0.75) | |
| Return On Capital Employed | (0.86) | (0.91) | |
| Return On Assets | (0.72) | (0.75) | |
| Return On Equity | (0.89) | (0.94) |
When accessing Immunome's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Immunome's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunome's profitability and make more informed investment decisions.
Evaluate Immunome's management efficiency
Immunome has return on total asset (ROA) of (0.3989) % which means that it has lost $0.3989 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.7636) %, meaning that it created substantial loss on money invested by shareholders. Immunome's management efficiency ratios could be used to measure how well Immunome manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of November 2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to drop to -0.91. At this time, Immunome's Total Assets are very stable compared to the past year. As of the 23rd of November 2024, Total Current Assets is likely to grow to about 151.9 M, while Net Tangible Assets are likely to drop about 10 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.04 | 6.34 | |
| Tangible Book Value Per Share | 6.04 | 6.34 | |
| Enterprise Value Over EBITDA | (4.08) | (4.28) | |
| Price Book Value Ratio | 1.77 | 1.86 | |
| Enterprise Value Multiple | (4.08) | (4.28) | |
| Price Fair Value | 1.77 | 1.86 | |
| Enterprise Value | 115.3 M | 121.1 M |
Leadership effectiveness at Immunome is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 34.6093 | Revenue 10.1 M | Quarterly Revenue Growth (0.18) | Revenue Per Share 0.189 | Return On Equity (2.76) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunome insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunome's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunome insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunome Corporate Filings
ASR | 22nd of November 2024 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Immunome Earnings per Share Projection vs Actual
Immunome Corporate Management
| Matthew Robinson | Chief Officer | Profile | |
| Michael Morin | Chief Scientist | Profile | |
| Philip Roberts | Chief Officer | Profile | |
| Robert Lapetina | Principal Officer | Profile | |
| JD Esq | General Officer | Profile | |
| Purnanand Sarma | CEO Pres | Profile | |
| Sandra Esq | Gen Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.